MIR155 (MicroRNA 155)

Circulating miRNAs represent a promising class of minimally invasive biomarkers and potential therapeutic targets; however, translation is constrained by biological context dependence and by pre-analytical and analytical variability. Standardized protocols and rigorously validated, subtype-aware biomarker panels will be essential for clinical implementation and for enabling miRNA-informed precision oncology in breast cancer.

In addition, neurotrophic therapies preserving BBB integrity may reduce secondary neuronal damage. Therefore, a future precision cardio-neuroprotective paradigm will rely on the integration of anti-inflammatory, molecular, and neurovascular strategies aimed at limiting systemic cytokine propagation and restoring bidirectional homeostasis through the heart-brain axis.

Six experimental studies using animal models were selected, which showed that agents such as doxorubicin, cisplatin, and methotrexate induce changes in domains such as memory, attention, and learning. These findings suggest that miRNAs play a central role in mediating the observed neurocognitive changes and may represent promising biomarkers and therapeutic targets to mitigate the effects of chemobrain. The study also highlights the need for future research integrating molecular and behavioral analyses to achieve more precise clinical applications.

Large-scale prospective validation studies are on the horizon to facilitate this implementation. All in all, international consortia and multi-center trials are required to test circulating miRNA biomarkers in real-world settings, ensuring they are feasible enough to guide routine oncological decision-making.

This is the first study comparing both SAT and VAT microRNA from the same cancer patients, stratified by adiposity assessed via CT-scan, showing depot-specific miRNA regulation. Our findings indicate that VAT is prone to metabolic dysregulation, with miR-155 emerging as a potential indicator of visceral fat remodeling.

Pro-regenerative environment was created through these combined effects in diabetic neuropathy that encourages axonal regeneration and the functional repair of injured neurons. ADSC-EXOs show promise as a potentially ground-breaking medicinal development, particularly for diabetic neuropathy.

P=N/A, N=100, Not yet recruiting, Assiut University

Analysis of microRNA expression levels in the blood plasma of CM patients can be used to assess the effectiveness of brachytherapy and to monitor patients within the framework of lifelong follow-up.

Adding 13 miRNAs to known risk factors and CA19-9 significantly improved the prediction performance for imminent PDAC risk, with AUCs of 85%, 77%, and 73% during the time windows of 1, 2, and 3 years prior to PDAC diagnosis. Findings of this large prospective study shield a light on the biology of PDAC and suggest a potential utility of monitoring circulating miRNAs for PDAC risk surveillance among high-risk individuals.

These findings support a competing endogenous RNA (ceRNA) model in which LIMASI sequesters pro-inflammatory miRNAs to modulate neuroinflammatory gene networks. Together, our data identify LIMASI as a putative ceRNA strongly associated with AD-related neuroinflammation and suggest that targeting LIMASI may represent a novel strategy to attenuate neuroinflammatory signaling and potentially slow AD-associated neurodegeneration.

Given these roles, circulating miR-155 has arisen as a promising non-invasive biomarker for metabolic abnormalities and a potential therapeutic target in MetS. This review highlights the multifaceted roles of miR-155 and summarizes accumulating evidence supporting its central involvement in the physiological and pathological mechanisms underlying MetS, with implications for early diagnosis and therapeutic development.